Media-OutReach Newswire The United Laboratories and Novo Nordisk announce exclusive license agreement for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Foreign nationals among 28 tourists feared killed in targeted terror attack in Indian-administered Kashmir 5.